Target ALS Foundation is an independent non-profit 501(c)(3) foundation working to accelerate ALS drug and biomarker development. Discovery of novel therapeutic targets rooted in a strong biological rationale is a key component towards achieving this goal....
Funding Awarded as Part of the Organization’s New $15 Million “Target ALS Diagnosis Initiative” Target ALS announced today the grantees receiving funding for new projects focused on ALS biomarker discovery and development, resulting from a call for proposals issued...
We speak to Dr. Robert Miller, Ph.D. about the intricacies of distributing ALS research funding. Learn about the process. Nonprofits bear a heavy burden when distributing endowments and grants toward projects that advance their organization’s mission. As groups like...
As the world begins the restoration project that is life after COVID-19, a major challenge will be establishing means to carefully return to daily activities. For Ludo Van Den Bosch of the Belgium-based Flanders Institute for Biotechnology (VIB), that means proceeding...
Today, Target ALS and The Association for Frontotemporal Degeneration (AFTD) announced $5 million in funding awards for work by six research teams to aid in the discovery of biomarkers and viable treatments for ALS and frontotemporal degeneration (FTD). ALS and FTD...
